Next Generation Gene Therapeutics is fast-tracking clinical trials in the US for its gene therapy candidates for Bietti’s crystalline dystrophy and classic phenylketonuria, supported by China data, the Chinese venture’s CEO says in an interview.
- Secured an opportunity with Mar de Miguel of BioWorld to discuss NGGT’s programs for macular degeneration and other eye diseases, leading to the article ASGCT: ‘From darkness to light’ in ocular gene therapy, published on May 14.
- https://www.bioworld.com/articles/708607-asgct-from-darkness-to-light-in-ocular-gene-therapy?v=preview
Comments are closed.